DMAC vs MAS · $157.4M cap vs P/E 18, rev $7.83B
DiaMedica Therapeutics Inc (DMAC) versus Masco Corporation (MAS) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Masco Corporation (MAS) is a building products & equipment company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported MAS revenue for 2024-12-31 was $7.83B. Net income was $874.0M. Revenue was down 1.7% from 2023-12-31 to 2024-12-31. MAS currently screens at market cap $14.00B and trailing P/E 18.1.
DMAC currently screens at market cap $157.4M. MAS currently screens at market cap $14.00B and trailing P/E 18.1.
Not investment advice. Open the DMAC and MAS stock pages for the full models.
Not investment advice.